Settlement Reached Between FEI, Show Jumper Paige Johnson

The Court of Arbitration for Sport (CAS) has approved a settlement between the Fédération Equestre Internationale (FEI) and U.S. jumper Paige Johnson in a substance reclassification case.

Samples taken Jan. 21, from the horse Luke Skywalker 46, ridden by Johnson at the CSI2* in Wellington, Florida, tested positive for the local anesthetic pramoxine. Following the FEI’s Tribunal’s decision to suspend Johnson for a year, the rider appealed to the CAS. 

As pramoxine will to be reclassified from a banned substance to controlled medication, effective from Jan. 1, 2018, the Johnson and the FEI ultimately agreed a settlement, which the CAS approved. Additional details on the decision are available online.

Under the terms of the settlement, the athlete’s period of ineligibility has been reduced from one year to three months, from April 5, 2017 (the date of notification) until July 5. Therefore, Johnson is now cleared to compete.

The CAS arbitration costs will be borne equally by the parties.

“Given the fact that pramoxine has been recently reclassified as a controlled medication, effective as of Jan. 1, 2018, the FEI agreed as a matter of fairness and based on the principle of proportionality, that the period of ineligibility initially imposed by the FEI Tribunal should be reduced,” said FEI Legal Director Mikael Rentsch. “Three months was deemed appropriate given the circumstances.”

Stay on top of the most recent Horse Health news with FREE weekly newsletters from TheHorse.com. Learn More